ReviewJournal of translational medicine2025
The immunological pathogenesis of vitiligo and the potential role of mesenchymal stromal/stem cells in its treatment.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of Serum Interleukin-17 Levels With Vitiligo: A Pilot Cross-Sectional Comparative Study.Cureus · 2026Article
- Neuropeptide Y drives vitiligo progression via NPYR-mediated NF-κB activation: a novel therapeutic target.Scientific reports · 2026Article
- Hotspots and Emerging Trends in JAK Inhibitor Therapy for Vitiligo: A Bibliometric Analysis (2015-2025).Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Vitiligo is a dermatological condition that affects millions of individuals globally and is frequently precipitated by damage to or dysfunction of melanocytes. Despite the availability of various therapeutic options, the management of vitiligo remains a significant challenge, underscoring the necessity for innovative treatment approaches. Currently, Mesenchymal Stromal Cells (MSCs) have gained prominence as a therapeutic modality in the research of numerous diseases, owing to their remarkable paracrine effects, making them a promising strategy for immunomodulation and tissue repair. The downregulation of specific cytokines by MSCs has the potential to enhance the microenvironment of vitiligo lesions, thereby contributing to therapeutic outcomes. This article aims to review the immunologic pathogenesis of vitiligo, the involvement of certain cytokines in its pathogenesis, and the therapeutic potential of MSCs in the treatment of vitiligo. It is anticipated that this review will serve as a reference for future therapeutic strategies involving MSCs in the management of vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.